Pulmatrix (PULM) and Cullgen Announce Proposed Merger
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Pulmatrix and Cullgen Announce Proposed Merger
November 13, 2024 9:00 AM ESTMerger to create a Nasdaq-listed company focusing on targeted protein degradation technology with
three degrader programs in or about to initiate Phase 1 clinical trials two for the treatment of cancer and
one for the treatment of acute and chronic pain
Combined company expected to have approximately $65 million of cash and cash equivalents at close to
provide funding through multiple clinical milestones and expected runway through 2026
As part of merger agreement, Pulmatrix intends... More
